The Rottenstein Law Group, which represents clients with claims stemming
from the severe side effects of the drug Fosamax, is taking all
necessary measures to comply with the latest order of the federal
Fosamax MDL court.
As the United States District Court for
the Southern District of New York prepares to wrap up the federal
Fosamax multidistrict litigation matter In Re: Fosamax Products
Liability Litigation (No. 06 MD 1789), Judge John F. Keenan has issued
an order designed to weed out those cases “more likely to be dismissed…
as they undergo closer scrutiny.” Defendant Merck & Co., Inc.,
manufacturer of the embattled osteoporosis drug, made a third request of
the court for a so-called “Lone Pine” order. Judge Keenan had denied Merck’s previous requests, but he granted this one.
By order filed November 20, 2012, Judge
Keenan is requiring each claimant whose federal lawsuit is part of the
Fosamax MDL but who has not alleged that he or she experienced
osteonecrosis of the jaw (ONJ) or osteomyellitis (as a result of having
taken Fosamax) to produce certain information and documentation to
identify specifically the alleged injuries suffered and to substantiate,
with expert testimony, to a “reasonable degree of medical certainty”
the claim that the injuries were caused by Fosamax.
For more information read more on: Rottenstein Law Group Heeds Fosamax MDL Court’s Order Designed to Weed Out Bad Cases